| Biomarker ID | 1585 |
| PMID | 25294917 |
| Year | 2014 |
| Biomarker | MDM2 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | Multivariate: HR: 1.73 (95% CI: 1.04–2.84) |
| Effect on Pathways | Pathway include: cell cycle, cell death, and angiogenesis pathways |
| Experiment | Distant Metastatis Vs No Distant Metastatis |
| Type of Biomarker | Prognostic |
| Cohort | 327 patients with prostate cancer were chosen for the study. 78 experienced Distant metastasis and 159 did not. 135 were competing death |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.036 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | Multivariate Model includes: Ki-67a; Cox-2a; p16a; MDM2 (≥184 vs. <184); Treatment (LTADT vs. STADT); Gleason score (≥8 vs. < 8); Stage (T3/4 vs. T2); Age (per year); Initial PSA (per 10 units); MDM2 cut-off: (≥184 vs. <184) |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |